Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

Nature Cancer 2026

View at publisher
Authors: Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, A. M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh
+12 more David A. Pattison, Sarennya Pathmanandavel, T. Hope, Narjess Ayati, M Hofman, Shahneen Sandhu, Claire Niu, Andrew Martin, Heidi Thomas, Martin R. Stockler, Ian D. Davis, on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group
DOI: 10.1038/s43018-026-01140-3
Cited by: 3
References: 27

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Nature Cancer
Publisher
Springer Science and Business Media LLC
Volume
7
Issue
4
Pages
622–630
Publication date
15 April 2026
Language
EN